Chronic Phase Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Chronic Phase clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Chronic Myeloid LeukemiaChronic Phase Chronic Myelogenous Leukemia
University of California, Irvine75 enrolled1 locationNCT06229860
Recruiting
Phase 2

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center50 enrolled1 locationNCT01746836
Recruiting
Not Applicable

Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia

Chronic Myelogenous Leukemia - Chronic Phase
Centre Hospitalier Henri Duffaut - Avignon60 enrolled1 locationNCT06082804
Recruiting
Phase 2

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Philadelphia Chromosome PositiveChronic Phase Chronic Myelogenous LeukemiaBCR-ABL1 Positive Chronic Myelogenous Leukemia+1 more
M.D. Anderson Cancer Center70 enrolled1 locationNCT05007873
Recruiting
Phase 2

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Leukemia, MyeloidChronic Myeloid Leukemia, Chronic PhaseLeukemia,Myeloid, Chronic+1 more
Augusta University100 enrolled7 locationsNCT05143840
Recruiting
Phase 1Phase 2

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

Chronic Myeloid LeukemiaChronic Myeloid Leukemia, Chronic Phase
Terns, Inc.180 enrolled54 locationsNCT06163430
Recruiting
Phase 1

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Chronic Myeloid LeukemiaCMLChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Enliven Therapeutics200 enrolled46 locationsNCT05304377
Recruiting

RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)

Chronic Myelogenous Leukemia in Chronic Phase
Novartis Pharmaceuticals40 enrolled4 locationsNCT06684964
Recruiting
Phase 1Phase 2

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Solid TumorsAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more
Incyte Biosciences International Sàrl70 enrolled25 locationsNCT03934372
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Phase 2

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Chronic Phase Chronic Myelogenous Leukemia
Medical College of Wisconsin51 enrolled4 locationsNCT04838041
Recruiting
Phase 2

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

Chronic Myeloid LeukemiaChronic Myeloid Leukemia, Chronic PhaseCML, Chronic Phase+1 more
Gruppo Italiano Malattie EMatologiche dell'Adulto160 enrolled11 locationsNCT06409936
Recruiting
Phase 1

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

CML (Chronic Myelogenous Leukemia)Chronic Phase CML
Enliven Therapeutics21 enrolled4 locationsNCT06787144
Recruiting

Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase
University of Pisa100 enrolled5 locationsNCT06119269
Recruiting
Phase 3

Study of Olverembatinib (HQP1351) in Patients With CP-CML

Chronic Myeloid LeukemiaCMLCML, Chronic Phase
Ascentage Pharma Group Inc.285 enrolled1 locationNCT06423911
Recruiting
Not Applicable

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

LeukemiaAcute Myeloid Leukemia in RemissionLymphoblastic Lymphoma+10 more
Medical College of Wisconsin40 enrolled1 locationNCT05794880
Recruiting

Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

Chronic Phase Ph+ Chronic Myeloid Leukemia
Il-Yang Pharm. Co., Ltd.168 enrolled2 locationsNCT06665412
Recruiting
Phase 3

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Chronic Myeloid Leukemia, Chronic PhaseCML, Chronic PhaseCML, Refractory+1 more
Il-Yang Pharm. Co., Ltd.173 enrolled18 locationsNCT03459534
Recruiting
Not Applicable

EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

Chronic Myeloid Leukemia (CML)Chronic Phase
University Hospital, Clermont-Ferrand160 enrolled16 locationsNCT03481868
Recruiting
Phase 1

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

CML, Chronic PhaseCML, Accelerated Phase
Jiangsu Hansoh Pharmaceutical Co., Ltd.108 enrolled1 locationNCT05367700